On the basis of region, the
global meningitis diagnostics testing market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America is
expected to hold dominant position in the global Meningitis
Diagnostic Testing Market over the forecast period, owing to early adoption
of diagnostic technologies by the major players. Moreover, major players in the
North America meningitis diagnostic testing market are focused on adopting
acquisition and collaboration strategies to enhance their market share. This in
turn is expected to boost the market growth. For instance, in September 2018,
Quest Diagnostics acquired the U.S. laboratory services business of Oxford Immunotec.
This acquisition is expected to expand capabilities of Quest Diagnostics in
infectious disease diagnostics to accelerate growth of the company by
increasing access to diagnostic innovation.
Meningitis is an infection
characterized by the inflammation of meninges. The meninges are the three layer
of protective tissue consisting of dura mater, arachnoid mater, and pia mater
that surround the neuraxis. Neuraxis represents the direction in which the
central nervous system lies. The most common causes of meningitis are bacteria
and viruses and less common causes include parasites and fungi. The symptoms of
meningitis include, severe headache, vomiting, fever, stiff neck, sensitivity
to light, and distinctive skin rash. Meningitis caused by bacteria is more
severe than that by virus. It is challenging to diagnose meningitis as it shows
most common symptoms. Meningitis can be diagnosed by performing blood test to
check for the presence of bacteria or viruses that can cause the disease.
Lumbar puncture can also be performed in which cerebrospinal fluid (CSF) is
taken from the base of the spine and checked for the presence of bacteria or
viruses. Bacterial meningitis can be treated with a combination of several
antibiotics.
Meningitis Diagnostic Testing
Market Drivers
Development of novel technologies
that require less time in diagnosis of meningitis is a major factor for
meningitis diagnostic testing market growth. For instance, in April 2018,
Ireland-based firm — HiberGene Diagnostics— introduced ‘HG Meningococcus test’—
a combination test for meningococcal and pneumococcal meningitis that offers
accurate results in as little as 40 minutes. The new test is expected to cover
90% cases of bacterial meningitis and help to speed up treatment of the
illness.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2418
Furthermore, increasing research
and development activities to diagnose various type of meningitis is expected
to boost growth of the meningitis diagnostic testing market during the forecast
period. For instance, in July 2018, Antrum Biotech and the University of Cape
Town developed a new rapid test that can diagnose tuberculosis (TB) meningitis
within two hours. The test is currently undergoing validation to enter the
market.
Meningitis Diagnostic Testing
Market- Regional Analysis
However, lack of access to newer
diagnostics technology by people in low income countries may restrain growth of
the market. Moreover, lack of diagnostic laboratory infrastructure in
developing countries is one of the major restraint for the Meningitis
Diagnostic Testing Market. Nevertheless, this can be improved by using test
that do not require laboratory support including rapid tests for use at the
point-of-care.
Furthermore, presence of key
players in Asia Pacific is expected to increase growth of the meningitis
diagnostics testing market in the region. For instance, in May 2017 Seegene
Inc., announced that it has entered into a new strategic collaboration
agreement with India-based Thermo Fisher Scientific. The collaboration was
filed to the U.S Food and Drug Administration (FDA) for clearance of AllplexTM
diagnostic assay by Seegene Inc. Thermo Fisher filed for U.S.FDA clearance to
run Seegene’s assays on Thermo Fisher’s QuantStudio 5 Real-Time PCR System.
Increasing prevalence of
meningitis in Africa is expected to contribute to significant growth of the
meningitis diagnostics market in the region. For instance, according to a
report by World Health Organization (WHO), February 2018, major epidemics of
meningococcal disease have occurred within the African meningitis belt
(Lapeysonnie). These epidemics are very disruptive, requiring the establishment
of emergency treatment centers to offer proper treatment to the patients in the
region.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/meningitis-diagnostic-testing-market-2418
Meningitis Diagnostic Testing
Market - Competitive Landscape
Some of the key players operating
in the market include, Thermo Fisher Scientific, Inc., BioFire Diagnostics,
Siemens, Quest Diagnostics, Bio-Rad Laboratories, Inc., Luminex Corporation,
Seegene Inc., IMMY, ELITechGroup, Abbott, Pfizer, Nuron Biotech, GSK,
MedImmune, Sanofi, Novartis, Baxter, Merck & Co., Biomed Pvt. Ltd, and
others.
Key Development
In 2018, Eurofins Viracor, Inc.,
has launched 16S Next Generation Sequencing (NGS) bacterial meningitis test for
the diagnosis of meningitis.
In 2018, Fast Track Diagnostics
entered into partnership with University of Liverpool to create a commercial
blood test to enhance the management and diagnosis of meningitis in patients.
In 2015, HiberGene Diagnostics,
has received CE mark approval for its HG Meningococcus, a rapid test for the
diagnosis of bacterial meningitis.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2418
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment